AUR PRO
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 042
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

Baylor College of Medicine, Indiana University Simon Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 046
Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, University of Chicago Medical Center, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 047
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Baylor, Dana-Farber/ Harvard Cancer Center, Duke, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Vanderbilt University

TBCRC 050
Niraparib in Combination with Trastuzumab in Metastatic HER2+ Breast Cancer

Mayo Clinic Cancer Center, Montefiore Medical Center,  University of Alabama at Birmingham, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2021 ASCO Poster

TBCRC 053
Pre-operative Pembrolizumab + Radiation Therapy in Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of North Carolina at Chapel Hill

Relevant Publications/Presentations: 2022 SABCS Poster

TBCRC 055
Radiation, Immunotherapy, and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Johns Hopkins University, University of Pennsylvania

Relevant Publications/Presentations: 2022 SABCS Poster

TBCRC 056
Niraparib + TSR042 in BRCA Mutated Breast Cancer

Dana-Farber/ Harvard Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University, Yale University

TBCRC 058
A Study of Enzalutamide, Enzalutamide in Combination with Mifepristone, or Chemotherapy in People with Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill

TBCRC 059
ETHAN - Endocrine Therapy for Male Breast Cancer

Dana-Farber/ Harvard Cancer Center, Georgetown University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, University of North Carolina at Chapel Hill

TBCRC 061
Biomarker Analysis of Patients with Breast Cancer Receiving Immunotherapy

Baylor College of Medicine, Montefiore Medical Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 062
STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Mayo Clinic Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, Vanderbilt University, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2023 SABCS Poster

TBCRC 063
Prospective Registry of Trastuzumab deruxtecan in Patients with Active/ Progressive HER2-Positive Breast Cancer Brain Metastases

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, University of California San Francisco, Yale University

TBCRC 065
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy with Curative Intent in de novo HER2+ Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, MD Anderson Cancer Center, University of North Carolina at Chapel Hill, Yale University